文献速递神经康复骨科与运动康复

机器人辅助治疗对卒中后上肢痉挛的效果:系统综述与荟萃分析

The effectiveness of robotic therapy in reducing upper limb spasticity in stroke survivors: a systematic review and meta-analysis.
PubMed 文献 · J Neuroeng Rehabil · 2026-03-02

该系统综述与荟萃分析纳入29项随机对照试验(n=1577),评估机器人辅助治疗(RAT)对比常规干预对卒中后上肢痉挛的效果。RAT对肘屈肌和腕屈肌痉挛有小幅但显著的改善,在多关节设备和慢性期试验中更明显,且不增加不良事件风险。RAT的主要价值在于安全提供高强度运动训练,而非一线抗痉挛治疗。

要点

  • RAT可小幅降低卒中后肘屈肌和腕屈肌痉挛,多关节设备及慢性期效果更明显。
  • RAT改善上肢运动功能(FMA MD 1.97),但日常生活活动能力和生活质量改善不一致。
  • RAT不增加治疗相关不良事件风险(OR 1.18),安全性良好。

核心结论

  • RAT是安全的方式,可适度降低卒中后肘屈肌和腕屈肌痉挛,获益多见于多关节设备和慢性期。
  • RAT的主要价值在于安全提供高强度运动训练,而非作为一线抗痉挛治疗。

研究设计与样本

  • 纳入标准为成人卒中后上肢痉挛的RAT对比非机器人干预的RCT,采用随机或固定效应模型合并,并用GRADE评估证据确定性。

主要发现

  • 肘屈肌痉挛改良Ashworth量表MD −0.25(95%CI −0.40至−0.10),主要见于慢性期试验。
  • 腕屈肌痉挛MD −0.22(95%CI −0.37至−0.08),多关节设备SMD −0.26(95%CI −0.43至−0.08)。
  • 肩内收肌痉挛和手部单一设备未发现显著降低。
  • 上肢运动功能Fugl-Meyer评估MD 1.97(95%CI 0.83至3.12),日常生活活动能力和生活质量改善不一致。
  • 治疗相关不良事件OR 1.18(95%CI 0.53至2.66),无显著差异。

关键数值与推荐

  • 肘屈肌痉挛MD −0.25(95%CI −0.40至−0.10),腕屈肌痉挛MD −0.22(95%CI −0.37至−0.08),多关节设备SMD −0.26(95%CI −0.43至−0.08)。
  • 上肢运动功能FMA MD 1.97(95%CI 0.83至3.12),不良事件OR 1.18(95%CI 0.53至2.66)。

临床怎么用

  • 对卒中后慢性期上肢痉挛患者,可考虑使用多关节RAT设备以小幅改善肘腕屈肌痉挛。
  • RAT应作为安全提供高强度运动训练的手段,而非替代一线抗痉挛治疗。

局限性

  • 纳入研究存在机器人技术多样、治疗方案异质性和结局报告方法学局限,尤其近端与远端痉挛测量混淆。
  • 证据确定性采用GRADE评估,但原文未报告具体分级结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Robot-assisted therapy (RAT) represents an evolving approach to post-stroke upper limb rehabilitation; however, its impact on spasticity modification remains inadequately characterized. Critical knowledge gaps persist due to the diversity of robotic technologies, heterogeneous treatment protocols, and methodological limitations in outcome reporting, particularly the conflation of proximal and distal spasticity measures. This systematic review and meta-analysis evaluated the comparative effectiveness of robotic versus conventional interventions for upper limb spasticity management, examining the influence of robotic design, stroke stage, and treatment dosage on spasticity outcomes. METHODS: We searched six databases and two trial registries up to November 2024 for RCTs of RAT versus non-robotic comparators in adults with post-stroke upper limb spasticity. Secondary outcomes included upper-limb motor function, activities of daily living, and health-related quality of life. We used random (I2 ≥ 50%) or fixed effects meta-analysis to synthesize results, with subgroup analyses for stroke phase, device type, and anatomical region. The certainty of evidence was assessed using GRADE. RESULTS: Twenty-nine RCTs (n = 1,577) were included. Overall, RAT produced a small but statistically significant reduction in elbow flexor spasticity on the Modified Ashworth Scale (MD − 0.25; 95% CI [− 0.40 to − 0.10]). This reduction was observed primarily in trials conducted in the chronic phase. Wrist flexor spasticity was also reduced (MD = − 0.22; 95% CI −0.37 to − 0.08). Reduction was also significant in studies using multi-joint devices (SMD − 0.26; 95% CI [− 0.43 to − 0.08]). In contrast, no significant reduction was found for shoulder adductor spasticity or for hand-only devices. RAT also improved motor function with Fugl-Meyer Assessment MD 1.97; 95% CI [0.83 to 3.12] but did not consistently improve ADL and quality of life. Importantly, there was no significant difference in the odds of treatment-related adverse events (OR 1.18; 95% CI [0.53 to 2.66]). CONCLUSIONS: This systematic review provides evidence that RAT is a safe modality that can modestly reduce elbow and wrist flexor spasticity in post-stroke patients. The benefit is specific, appearing more robust with multi-joint devices and in the chronic phase of recovery. The primary value of RAT seems to be in safely delivering high-intensity motor practice rather than acting as a first-line anti-spasticity treatment. Registration PROSPERO CRD 42024615294.

来源:J Neuroeng Rehabil,查看原文。版权归原作者所有。

引用

  1. Facciorusso S, Esquenazi A, Molteni F, et al. The effectiveness of robotic therapy in reducing upper limb spasticity in stroke survivors: a systematic review and meta-analysis. J Neuroeng Rehabil. 2026. PMID: 41772621. doi:10.1186/s12984-026-01925-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。